Brief: Matinas Biopharma Reports Successful Treatment Of Patient With Limb-Threatening Mucor Infection In Its Oral Mat2203 Compassionate/Expanded Use Access Program
24/06/2024 15:34
June 24 (Reuters) - Matinas BioPharma Holdings Inc
MTNB.A :
* MATINAS BIOPHARMA REPORTS SUCCESSFUL TREATMENT OF PATIENT
WITH
LIMB-THREATENING MUCOR INFECTION IN ITS ORAL MAT2203
COMPASSIONATE/EXPANDED USE ACCESS PROGRAM
Source text for Eikon: ID:nGNXbM4rGl
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing